A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.
A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study Evaluating The Efficacy And Safety Of Latanoprost And Timolol In Pediatric Subjects With Glaucoma.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
-
Leuven, Belgien, 3000
- Pfizer Investigational Site
-
-
-
-
-
Regenstauf, Deutschland, 93128
- Pfizer Investigational Site
-
Schorndorf, Deutschland, 73614
- Pfizer Investigational Site
-
-
-
-
-
Lille Cedex, Frankreich, 59037
- Pfizer Investigational Site
-
Lyon, Frankreich, 69437
- Pfizer Investigational Site
-
-
Cedex 1
-
Amiens, Cedex 1, Frankreich, 80054
- Pfizer Investigational Site
-
-
-
-
Andhra Pradesh
-
Hyderabad, Andhra Pradesh, Indien, 500034
- Pfizer Investigational Site
-
-
Gujarat
-
Ahmedabad, Gujarat, Indien, 380004
- Pfizer Investigational Site
-
-
Tamilnadu
-
Coimbatore, Tamilnadu, Indien, 641 014
- Pfizer Investigational Site
-
-
-
-
-
Catania, Italien, 95123
- Pfizer Investigational Site
-
Milano, Italien, 20162
- Pfizer Investigational Site
-
-
-
-
Antioquia
-
Medellín, Antioquia, Kolumbien, 0000
- Pfizer Investigational Site
-
-
Cundinamarca
-
Bogota, Cundinamarca, Kolumbien, 0000
- Pfizer Investigational Site
-
-
-
-
-
Makati City, Philippinen, 1200
- Pfizer Investigational Site
-
Mandaluyong City, Philippinen, 1500
- Pfizer Investigational Site
-
-
-
-
-
Bialystok, Polen, 15-274
- Pfizer Investigational Site
-
Gdansk, Polen, 80-211
- Pfizer Investigational Site
-
Wroclaw, Polen, 50-368
- Pfizer Investigational Site
-
-
-
-
-
Coimbra, Portugal, 3000-548
- Pfizer Investigational Site
-
Lisboa, Portugal, 1649-035
- Pfizer Investigational Site
-
Lisboa, Portugal, 1169-019
- Pfizer Investigational Site
-
Lisboa, Portugal, 1169-097
- Pfizer Investigational Site
-
Porto, Portugal, 4099-001
- Pfizer Investigational Site
-
-
-
-
Cluj
-
Cluj-Napoca, Cluj, Rumänien, 400006
- Pfizer Investigational Site
-
-
-
-
-
Moscow, Russische Föderation, 119331
- Pfizer Investigational Site
-
St. Petersburg, Russische Föderation, 194100
- Pfizer Investigational Site
-
-
-
-
-
Belgrade, Serbien, 11000
- Pfizer Investigational Site
-
-
-
-
-
Bratislava, Slowakei, 83340
- Pfizer Investigational Site
-
-
-
-
-
Ljubljana, Slowenien, 1000
- Pfizer Investigational Site
-
-
-
-
-
Madrid, Spanien, 28040
- Pfizer Investigational Site
-
Sevilla, Spanien, 41013
- Pfizer Investigational Site
-
-
Barcelona
-
Esplugues de Llobregat, Barcelona, Spanien, 08950
- Pfizer Investigational Site
-
-
-
-
-
Myfair West, Südafrika, 2109
- Pfizer Investigational Site
-
-
-
-
-
Praha 5, Tschechien, 150 06
- Pfizer Investigational Site
-
-
-
-
-
Kharkiv, Ukraine, 61000
- Pfizer Investigational Site
-
Kyiv, Ukraine
- Pfizer Investigational Site
-
Kyiv, Ukraine, 04050
- Pfizer Investigational Site
-
Kyiv, Ukraine, 01135
- Pfizer Investigational Site
-
Odesa, Ukraine, 65061
- Pfizer Investigational Site
-
-
-
-
Florida
-
Pembroke Pines, Florida, Vereinigte Staaten, 33028
- Pfizer Investigational Site
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30322
- Pfizer Investigational Site
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46202
- Pfizer Investigational Site
-
-
Minnesota
-
Minneapolis, Minnesota, Vereinigte Staaten, 55455
- Pfizer Investigational Site
-
-
Nevada
-
Henderson, Nevada, Vereinigte Staaten, 89052
- Pfizer Investigational Site
-
Henderson, Nevada, Vereinigte Staaten, 89074
- Pfizer Investigational Site
-
Las Vegas, Nevada, Vereinigte Staaten, 89148
- Pfizer Investigational Site
-
-
-
-
-
Birmingham, Vereinigtes Königreich, B18 7QH
- Pfizer Investigational Site
-
London, Vereinigtes Königreich, EC1V 2PD
- Pfizer Investigational Site
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Male or female of 18 years of age or under
- Diagnosis of glaucoma
- IOP of 22 mmHg or above in at least 1 eye
Exclusion Criteria:
- Require surgery for acute angle closure
- Have had prior cyclodestructive procedures
- Have a history of ocular trauma or surgery in either eye within 3 months of the baseline visit
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Aktiver Komparator: Timolol
|
Timolol 0.5% dosed twice-daily
|
|
Experimental: latanoprost
|
Latanoprost 0.005% ophthalmic solution dosed once-daily
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Reduction From Baseline in Mean IOP at Week 12, Last Observation Carried Forward (LOCF)
Zeitfenster: Baseline, Week 12
|
Calculated as Baseline IOP minus Week 12 IOP, LOCF.
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were less than or equal to (≤) 2 millimeters of mercury (mmHg) of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Baseline, Week 12
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Reduction From Baseline in Mean IOP at Week 1
Zeitfenster: Baseline, Week 1
|
Calculated as Baseline IOP minus Week 1 IOP (observed).
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Baseline, Week 1
|
|
Reduction From Baseline in Mean IOP at Week 4
Zeitfenster: Baseline, Week 4
|
Calculated as Baseline IOP minus Week 4 IOP (observed).
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Baseline, Week 4
|
|
Reduction From Baseline in Mean IOP at Week 12 (Observed)
Zeitfenster: Baseline, Week 12
|
Calculated as Baseline IOP minus Week 12 IOP (observed).
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Baseline, Week 12
|
|
Mean IOP at Baseline
Zeitfenster: Baseline
|
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Baseline
|
|
Mean IOP at Week 1
Zeitfenster: Week 1
|
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Week 1
|
|
Mean IOP at Week 4
Zeitfenster: Week 4
|
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Week 4
|
|
Mean IOP at Week 12
Zeitfenster: Week 12
|
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Week 12
|
|
Percentage of Participants With Greater Than or Equal to (≥) 15% IOP Reduction From Baseline at Both Weeks 4 and 12
Zeitfenster: Baseline, Week 4, and Week 12
|
Participants with ≥15% IOP reduction from baseline at both Week 4 and Week 12. Calculated as (post baseline IOP minus baseline IOP) divided by IOP, multiplied by 100%.
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Baseline, Week 4, and Week 12
|
|
Percentage of Participants Discontinuing Therapy Due to a Drug-related Adverse Experience
Zeitfenster: Baseline through Week 12
|
An investigator's causality assessment was the determination of whether there existed a reasonable possibility that the investigational product caused or contributed to an adverse event (AE).
If the investigator did not know whether or not investigational product caused the event, then the event was handled as "related to investigational product" for reporting purposes.
|
Baseline through Week 12
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Augenkrankheiten
- Okuläre Hypertonie
- Glaukom
- Physiologische Wirkungen von Arzneimitteln
- Adrenerge Beta-Antagonisten
- Adrenerge Antagonisten
- Adrenerge Wirkstoffe
- Neurotransmitter-Agenten
- Molekulare Mechanismen der pharmakologischen Wirkung
- Anti-Arrhythmie-Mittel
- Antihypertensive Mittel
- Pharmazeutische Lösungen
- Ophthalmische Lösungen
- Timolol
- Latanoprost
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- A6111137
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .